Nicotine River LLC

DUBLIN, July 15, 2022 /PRNewswire/ -- The "Smoking Cessation and Nicotine De-Addiction Products Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's offering. The report on the global smoking cessation and nicotine de-addiction products market provides qualitative and quantitative analysis for the period from 2022 to 2028. The report predicts the global smoking cessation and nicotine de-addiction products market to grow with a CAGR of about 15% over the forecast period from 2022-2028. The study on smoking cessation and nicotine de-addiction products market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2022 to 2028. The report on smoking cessation and nicotine de-addiction products market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global smoking cessation and nicotine de-addiction products market over the period of 2022 to 2028. Moreover, the report is a collective presentation of primary and secondary research findings. Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global smoking cessation and nicotine de-addiction products market over the period of 2022 to 2028. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider. Report Findings 1) Drivers Growing health consciousness among cigarette smokers Accessibility to a large range of nicotine replacement therapy (NRT) products 2) Restraints High cost associated with smoking cessation products 3) Opportunities New product innovations What does this Report Deliver? 1. Comprehensive analysis of the global as well as regional markets of the smoking cessation and nicotine de-addiction products market. 2. Complete coverage of all the segments in the smoking cessation and nicotine de-addiction products market to analyze the trends, developments in the global market and forecast of market size up to 2028. 3. Comprehensive analysis of the companies operating in the global smoking cessation and nicotine de-addiction products market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company. 4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify. Key Topics Covered: 1. Preface 2. Executive Summary 3. Global Smoking Cessation and Nicotine De-addiction Products Market Overview 3.1. Introduction 3.2. Market Dynamics 3.2.1. Drivers 3.2.2. Restraints 3.2.3. Opportunities 3.3. Analysis of COVID-19 impact on the Smoking Cessation and Nicotine De-addiction Products Market 3.4. Porter's Five Forces Analysis 3.5. Growth Matrix Analysis 3.5.1. Growth Matrix Analysis by Type 3.5.2. Growth Matrix Analysis by Distribution Channel 3.5.3. Growth Matrix Analysis by Region 3.6. Value Chain Analysis of Smoking Cessation and Nicotine De-addiction Products Market 4. Smoking Cessation and Nicotine De-addiction Products Market Macro Indicator Analysis 5. The Global Smoking Cessation and Nicotine De-addiction Products Market by Type 5.1. E-cigarettes 5.2. Drug Therapy 5.3. Nicotine Replacement Therapies 6. Global Smoking Cessation and Nicotine De-addiction Products Market by Distribution Channel 6.1. Drug Store 6.2. Retail Pharmacies 6.3. Hospital Pharmacies 6.4. Online Pharmacies 7. Global Smoking Cessation and Nicotine De-addiction Products Market by Region 2022-2028 8. Company Profiles and Competitive Landscape 8.1. Competitive Landscape in the Global Smoking Cessation and Nicotine De-addiction Products Market 8.2. Companies Profiled 8.2.1. Takeda Pharmaceutical Co., Ltd. 8.2.2. Pfizer, Inc. 8.2.3. NJOY, Inc. 8.2.4. Imperial Tobacco Company of India Limited. 8.2.5. Cipla Ltd. 8.2.6. Revolymer PLC 8.2.7. Novartis International AG 8.2.8. McNeil AB 8.2.9. Glaxo Smith Kline PLC 8.2.10. Others For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Potential Rule Would Propose to Establish a Maximum Level of Nicotine in Cigarettes with the Goal of Reducing Youth Use, Addiction and Death SILVER SPRING, Md., June 21, 2022 /PRNewswire/ -- Today, the Biden-Harris Administration published plans for future potential regulatory actions that include the U.S. Food and Drug Administration's plans to develop a proposed product standard that would establish a maximum nicotine level to reduce the addictiveness of cigarettes and certain other combusted tobacco products. The goal of the potential rule would be to reduce youth use, addiction and death. Each year, 480,000 people die prematurely from a smoking-attributed disease, making tobacco use the leading cause of preventable disease and death in the United States. Additionally, tobacco use costs nearly $300 billion a year in direct health care and lost productivity. While nicotine is not what makes smoking cigarettes so toxic, it's the ingredient that makes it very hard to quit smoking. Addiction to nicotine in combusted products is the main driver of sustained use of these products. In fact, more than half of adult cigarette smokers make a serious quit attempt each year (quitting for at least a day), but most do not succeed due to the addictive nature of cigarettes. Such a product standard, if proposed and then finalized after a thorough process, would make those products minimally- or non-addictive. " Nicotine is powerfully addictive," said FDA Commissioner Robert M. Califf, M.D. "Making cigarettes and other combusted tobacco products minimally addictive or non-addictive would help save lives. The U.S. Surgeon General has reported that 87 percent of adult smokers start smoking before age 18, and about two-thirds of adult daily smokers began smoking daily by 18 years of age. Lowering nicotine levels to minimally addictive or non-addictive levels would decrease the likelihood that future generations of young people become addicted to cigarettes and help more currently addicted smokers to quit." A paper published by the FDA in the New England Journal of Medicine in 2018 projected that by year 2100, a potential nicotine product standard could result in more than 33 million people not becoming regular smokers, a smoking rate of only 1.4%, and more than 8 million fewer people dying from tobacco-related illnesses. The current smoking rate is 12.5%. The Spring 2022 Unified Agenda of Regulatory and Deregulatory actions published today provides a report on the actions administrative agencies are considering issuing in the near and long term and currently lists several planned potential regulatory actions related to tobacco products; however, the dates in the Unified Agenda are not intended to be a precise estimate of when the work necessary to complete a proposed rule will be finished nor a final decision regarding whether a rule will be proposed. The FDA also remains focused on its regulatory oversight of e-cigarettes and other electronic nicotine delivery systems (ENDS). Thus far, FDA has taken action on approximately 99% of the nearly 6.7 million products for which applications were received by the Sept. 9, 2020, deadline, including issuing marketing denial orders for more than 1 million ENDS products. The FDA has also issued warning letters to ENDS product manufacturers and retailers who continue to sell products that are illegally on the market. The agency is focused on expeditiously completing the review of the remaining applications we received by the Sept. 9 deadline with a focus on those products with large market share. In addition, the FDA has made a significant investment in a multimedia e-cigarette public education campaign aimed at the nearly 10.7 million youth aged 12-17 who have ever used e-cigarettes or are open to trying them highlighting information about the potential risks of e-cigarette use. Additional Resources: Nicotine Is Why Tobacco Products Are Addictive What Is Nicotine? Media Contact: FDA Office of Media Affairs, 301-796-4540 Consumer Inquiries: Email or 888-INFO-FDA (888-463-0332) The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products. SOURCE U.S. Food and Drug Administration

Dublin, Aug. 17, 2021 (GLOBE NEWSWIRE) -- The "Smoking Cessation Aids Market Forecast to 2028 - COVID-19 Impact and Global Analysis by\ Product (Nicotine Replacement Therapy, Drugs, Electronic Cigarettes, and Others) and End-User (Hospital Pharmacies, Online Channel, Retail Pharmacies, and Other End Users)" report has been added to ResearchAndMarkets.com's offering. According to this report the market is expected to reach US$ 64,032.30 million in 2028 from US$ 23,413.08 million in 2021. The market is estimated to grow with a CAGR of 15.5% from 2021-2028. Key factors that are driving the growth of this market are rising addiction toward tobacco smoking, increasing number of campaigns to reduce smoking and tobacco dependence. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.Based on end-user, the smoking cessation aids market is segmented into hospital pharmacies, online channel, retail pharmacies, and other end users. The retail pharmacies segment is likely to hold the largest share of the market in 2021, however the online channel segment is anticipated to register the highest CAGR of the market during the forecast period.The substance and tobacco abuse treatment industry is getting competitive every consecutive year with the introduction of new and innovative therapies by the smoking cessation aids market players. For instance, in July 2020, Dr Reddy's Laboratories announced the launch of over-the-counter Nicotine Polacrilex lozenges in the American market. The company launched Nicotine Polacrilex lozenges in the strengths of 2 mg and 4 mg in the US. Furthermore, the top players in the market are also collaborating with third parties to improve their existing product range of smoking cessation aids. For instance, in March 2016, GlaxoSmithKline partnered with a digital smoking cessation company 2Morrow to offer the GSK's Nicoderm CQ Patch to smokers who complete 2morrow's cessation program.In addition, medical devices such as nicotine-free e-cigarettes and vapes are being launched by market players at local and regional levels. For instance, the US based electronic cigarette company Juul Labs announced to launch its products in India by the end of 2019. In December 2018, the British American Tobacco (BAT) introduced two new e-cigarettes named Vype iSwitch Maxx and Vype iSwitch in five of BAT's VIP stores in London. Thus, the consistent launch of new and innovative smoking cessation aids would become a prevalent trend in the smoking cessation aids market in the coming years.COVID-19 outbreak was first observed in December 2019 in Wuhan (China), and it has spread to more than 100 countries across the world, with the World Health Organization (WHO) stating it as a public health emergency. The global impacts of COVID-19 are being felt across several markets. The findings show that e-cigarette usage and dual use of e-cigarettes and cigarettes are important underlying risk factors for COVID-19 that have previously not been established. As per the researchers, smoking is a risk factor for influenza, patients who smoke are immunosuppressed to some degree, and they make more mucus.Pfizer Inc.; GlaxoSmithKline plc.; Dr. Reddy's Laboratories; Johnson and Johnson Services, Inc.; Cipla Inc.; Perrigo Company plc; Bausch Health Companies Inc.; Glenmark; NJOY; and Juul Labs are among the leading companies operating in the smoking cessation aids market. Reasons to Buy Key Topics Covered: 1. Introduction 2. Smoking Cessation Aids Market - Key Takeaways 3. Research Methodology 4. Global Smoking Cessation Aids Market - Market Landscape4.1 Overview4.2 PEST Analysis4.3 Expert Opinions 5. Smoking Cessation Aids Market - Key Market Dynamics5.1 Market Drivers5.1.1 Rising Addiction of Tobacco Smoking5.1.2 Increasing Awareness Activities and Campaigns to Reduce Tobacco Usage and Dependence5.2 Market Restraints5.2.1 Steeping Costs for Development of Nicotine Replacement Therapies5.3 Market Opportunities5.3.1 E-cigarette Epidemic Among Youth5.4 Future Trends5.4.1 Introduction of New Smoking Cessation Aids5.5 Impact Analysis 6. Smoking Cessation Aids Market - Global Analysis6.1 Global Smoking Cessation Aids Market Revenue Forecast and Analysis6.2 Global Smoking Cessation Aids Market, By Geography - Forecast and Analysis6.3 Market Positioning of Key Players 7. Smoking Cessation Aids Market Analysis - By Product7.1 Overview7.2 Smoking Cessation Aids Market Revenue Share, by Product (2021 and 2028)7.3 Nicotine Replacement Therapy7.3.1 Overview7.3.2 Nicotine Replacement Therapy: Smoking Cessation Aids Market - Revenue and Forecast to 2028 (US$ Million)7.4 Drugs7.4.1 Overview7.4.2 Drugs: Smoking Cessation Aids Market - Revenue and Forecast to 2028 (US$ Million)7.5 Electronic Cigarettes7.5.1 Overview7.5.2 Electronic Cigarettes: Smoking Cessation Aids Market - Revenue and Forecast to 2028 (US$ Million)7.6 Others7.6.1 Overview7.6.2 Others: Smoking Cessation Aids Market - Revenue and Forecast to 2028 (US$ Million) 8. Smoking Cessation Aids Market Analysis - By End-User8.1 Overview8.2 Smoking Cessation Aids Market Share, by End-User, 2021 and 2028, (%)8.3 Hospital Pharmacies8.3.1 Overview8.3.2 Hospital Pharmacies: Smoking Cessation Aids Market - Revenue and Forecast to 2028 (US$ Million)8.4 Online Channel8.4.1 Overview8.4.2 Online Channel: Smoking Cessation Aids Market - Revenue and Forecast to 2028 (US$ Million)8.5 Retail Pharmacies8.5.1 Overview8.5.2 Retail Pharmacies: Smoking Cessation Aids Market - Revenue and Forecast to 2028 (US$ Million)8.6 Other End Users8.6.1 Overview8.6.2 Other End Users: Smoking Cessation Aids Market - Revenue and Forecast to 2028 (US$ Million) 9. Smoking Cessation Aids Market - Geographic Analysis 10. Impact of COVID-19 Pandemic on Global Smoking Cessation Aids Market10.1 North America: Impact Assessment of COVID-19 Pandemic10.2 Europe: Impact Assessment Of COVID-19 Pandemic10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic10.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic10.5 South and Central America: Impact Assessment of COVID-19 Pandemic 11. Industry Landscape11.1 Overview11.2 Growth Strategies Done by the Companies in the Market, (%)11.3 Organic Developments11.3.1 Overview11.4 Inorganic Developments11.4.1 Overview 12. Company Profiles12.1 Pfizer Inc.12.1.1 Key Facts12.1.2 Business Description12.1.3 Products and Services12.1.4 Financial Overview12.1.5 SWOT Analysis12.1.6 Key Developments12.2 GlaxoSmithKline plc.12.2.1 Key Facts12.2.2 Business Description12.2.3 Products and Services12.2.4 Financial Overview12.2.5 SWOT Analysis12.2.6 Key Developments12.3 Dr. Reddy's Laboratories12.3.1 Key Facts12.3.2 Business Description12.3.3 Products and Services12.3.4 Financial Overview12.3.5 SWOT Analysis12.3.6 Key Developments12.4 Johnson and Johnson Services, Inc.12.4.1 Key Facts12.4.2 Business Description12.4.3 Products and Services12.4.4 Financial Overview12.4.5 SWOT Analysis12.4.6 Key Developments12.5 Cipla Inc.12.5.1 Key Facts12.5.2 Business Description12.5.3 Products and Services12.5.4 Financial Overview12.5.5 SWOT Analysis12.5.6 Key Developments12.6 Perrigo Company plc12.6.1 Key Facts12.6.2 Business Description12.6.3 Products and Services12.6.4 Financial Overview12.6.5 SWOT Analysis12.6.6 Key Developments12.7 Bausch Health Companies Inc.12.7.1 Key Facts12.7.2 Business Description12.7.3 Products and Services12.7.4 Financial Overview12.7.5 SWOT Analysis12.7.6 Key Developments12.8 Glenmark12.8.1 Key Facts12.8.2 Business Description12.8.3 Products and Services12.8.4 Financial Overview12.8.5 SWOT Analysis12.8.6 Key Developments12.9 NJOY12.9.1 Key Facts12.9.2 Business Description12.9.3 Products and Services12.9.4 Financial Overview12.9.5 SWOT Analysis12.9.6 Key Developments12.10 Juul Labs12.10.1 Key Facts12.10.2 Business Description12.10.3 Products and Services12.10.4 Financial Overview12.10.5 SWOT Analysis12.10.6 Key Developments 13. Appendix For more information about this report visit